Fred Alger Management Reduces Eli Lilly Holdings

Investment firm cuts stake in pharmaceutical giant by over 39%

Mar. 16, 2026 at 11:22am

Got story updates? Submit your updates here. ›

Fred Alger Management LLC, an institutional investor, decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 39.2% during the third quarter, according to a recent SEC filing. The firm's stake in Eli Lilly is now valued at $73.085 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a diverse portfolio of drugs and therapies. Changes in major institutional investors' holdings can signal shifts in market sentiment and influence the company's stock price performance.

The details

According to the 13F filing, Fred Alger Management sold 61,822 Eli Lilly shares in the third quarter, reducing its total position to 95,787 shares. The firm cited portfolio rebalancing and other investment considerations as the reasons for the reduction in its Eli Lilly holdings.

  • The 13F filing was submitted on March 16, 2026, covering the third quarter of 2025.

The players

Fred Alger Management LLC

An institutional investment management firm based in New York City.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana, that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Fred Alger Management's Eli Lilly holdings reflects the firm's investment strategy and portfolio management decisions, but does not necessarily indicate broader market sentiment or the long-term prospects of the pharmaceutical company.